Highbridge Capital Management's Q3 2022 vs. Q4 2022 13F Holdings Comparison

In the world of finance, the quarterly 13F filings offer investors a glimpse into the holdings of some of the most significant institutional investors. Highbridge Capital Management LLC, a hedge fund founded in 1992 by Glenn Dubin and Henry Swieca, is no exception. In this analysis, we examine Highbridge's Q3 2022 vs. Q4 2022 13F holdings to determine its current portfolio.

At the end of Q4 2022, Highbridge's portfolio showed a total value of $1.8 billion, a 2.4% decrease from the previous quarter. The fund's top holdings included the SPDR S&P 500 ETF TR and Occidental Pete Corp, with 700,000 and 1,297,000 shares respectively.

Among Highbridge's biggest increases in holdings were GFL Environmental Inc. and MannKind Corp. The former saw a 25.2% increase in shares, while the latter had a 34.3% increase. On the downside, the fund's holdings in Fastly Inc decreased by a staggering 97.3% during the period.

In the healthcare sector, Highbridge decreased its holding in Sarepta Therapeutics Inc by 11.7%, Collegium Pharmaceutical Inc by 0.1%, and Integra LifeSciences Hldgs by 11.8%. In contrast, the fund increased its holdings in Amryt Pharma Plc and Viavi Solutions Inc by 5.5% and 10.3% respectively.

Highbridge also increased its holdings in several special-purpose acquisition companies (SPACs), including Kensington Capital Acquisition Corp II, Ciig Capital Partners II Inc, and Gore Holdings IX Inc. The increases ranged between 1.1% and 8.4%.

In conclusion, Highbridge Capital Management's Q3 2022 vs. Q4 2022 13F holdings show a mix of ups and downs. While some of its holdings decreased, the fund increased its holdings in other companies. With SPACs gaining in popularity, Highbridge's higher-than-average investments in the sector are worth noting. Overall, investors will want to keep an eye on Highbridge's future filings to see how the fund continues to manage its portfolio.